神经退行性疾病的表观遗传编排:黄素作为治疗的潜在目标
1Department of Paramedical Sciences, Faculty of Allied Health Sciences, SGT University, Gurugram, 122505, Haryana, India. shweta_fahs@sgtuniversity.org.
Neurochemical research
|June 10, 2024
概括
表观遗传变化导致神经系统疾病,如阿尔茨海默氏症和帕金森病. 黄素通过调节这些表观遗传因素和线粒体功能来显示潜在的神经保护作用.
科学领域:
- 神经科学是一个神经科学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 与年龄相关的神经系统疾病,包括阿尔茨海默氏症 (AD),帕金森病 (PD) 和亨廷顿病 (HD),具有共同的机制,如氧化应激和线粒体功能障碍.
- 表观遗传调节显著影响基因表达,并与这些神经退行性疾病的发病和进展有关.
- 聚醇,特别是黄素,表现出抗氧化和神经保护性质,新出现的证据表明它在表观遗传调节中的作用.
研究的目的:
- 审查线粒体功能障碍和表观遗传调节在与年龄相关的神经疾病 (AD,PD,HD,ALS,MS) 中的作用.
- 通过表观遗传调节来总结黄素在预防和治疗这些疾病方面的神经保护作用.
- 为了突出库尔库介导的神经保护中的表观遗传调制的有限但越来越多的证据.
主要方法:
- 文献综述侧重于神经退行性疾病中的线粒体功能障碍,表观遗传学和线粒体表观遗传学.
- 对研究黄素抗氧化和神经保护作用的研究进行分析.
- 检查黄素对表观遗传调节器和细胞解毒系统的影响的研究.
主要成果:
- 线粒体功能障碍和表观遗传改变是神经退行症的关键因素.
- 黄素显示出显著的抗氧化和神经保护能力.
- 有证据表明,黄素可以调节表观遗传机制,影响排毒系统,并可能减轻神经炎症.
结论:
- 线粒体遗传学为理解神经退行性疾病机制提供了一个框架.
- 由于其表观遗传调节功能,黄素作为神经退行性疾病的治疗剂具有前途.
- 需要进一步的研究来充分阐明黄素介导的神经保护中的表观遗传调节机制.
更多相关视频
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Human Genetics
559
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
559
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462


